Pan African Clinical Trials Registry

South African Medical Research Council, South African Cochrane Centre
PO Box 19070, Tygerberg, 7505, South Africa
Telephone: +27 21 938 0835 or +27 21 938 0967
Email: pactradmin@mrc.ac.za Website: pactr.samrc.ac.za
Trial no.: PACTR202607461619486 Date of Registration: 20/07/2026
Trial Status: Registered in accordance with WHO and ICMJE standards
TRIAL DESCRIPTION
Public title First-in-Human Therapeutic Targeting of MYCN driven Pediatric and Adult Cancers by the 3'UTRMYCN M1-14+IO-Nanocage
Official scientific title First-in-Human (FIH) Phase 1 Clinical Trial of the 3'UTRMYCN M1-14 for MYCN Driven Pediatric and Adult Cancers
Brief summary describing the background and objectives of the trial Background Summary MYCN is over expressed in many cancers and has remained undruggable. We have pre-clinical evidence of the novel therapeutic agent, the 3'UTRMYCNM1-14+IO-Nanocage being effective in downregulating MYCN in pan MYCN driven cancers in-vivo such as in rhabdomyosarcoma, neuroblastoma, NEPC, SCLC and medulloblastoma. Therefore, the objective of this trial is to establish: 1. The safety and tolerability of the drug. 2. To determine the preliminary efficacy 3. To determine the PK/PD
Type of trial Non-Randomised
Acronym (If the trial has an acronym then please provide)
Disease(s) or condition(s) being studied Cancer,Paediatrics
Sub-Disease(s) or condition(s) being studied
Purpose of the trial Treatment: Drugs
Anticipated trial start date 20/01/2027
Actual trial start date 22/12/2027
Anticipated date of last follow up 15/03/2028
Actual Last follow-up date 22/03/2028
Anticipated target sample size (number of participants) 56
Actual target sample size (number of participants)
Recruitment status Not yet recruiting
Publication URL
Secondary Ids Issuing authority/Trial register
STUDY DESIGN
Intervention assignment Allocation to intervention If randomised, describe how the allocation sequence was generated Describe how the allocation sequence/code was concealed from the person allocating the participants to the intervention arms Masking If masking / blinding was used
Single Group Non-randomised Numbered containers Open-label(Masking Not Used)
INTERVENTIONS
Intervention type Intervention name Dose Duration Intervention description Group size Nature of control
Experimental Group 3UTRMYCN M14 In this Phase 1 part, groups of 3 patients will receive intravenous (IV) injection of single ascending doses of 3’UTRMYCN M1-14 +IO-Nanocage The treatment will start with a dose of 3.5mg of 3’UTRMYCN M1-14, followed by doses of 7mg, 14mg, 28mg, 56mg. A single dose will be administered IV to each patient. In the Phase 2 part, RP2D will be dosed 2x per week for 12 weeks. 1yr The generic name of the drug is 3’UTRMYCNM1-14 and the trade name of the drug is UTRxMYCNM1-14. The drug is a synthetic engineered destabilizing 3’UTR of MYCN and consists of C8344H10512N3110O5175P854 with a molecular weight of 263622.1, and a GC content of 46.8% and a length of 855 bases. The drug is a new class of cancer therapeutics which destabilizes the target oncogenic mRNA specifically by recognizing site specific mRNA targets and switching the ribosomes to degrade it. The drug is a new class of cancer therapeutics, which destabilizes the target oncogenic mRNA specifically by recognizing site specific mRNA targets and switching the ribosomes to degrade it. 3’UTRMYCNM1-14 is a synthetic mRNA-based investigational therapy targeting MYCN-driven cancers. The drug degrades MYCN mRNA via a site-specific ribosomal targeting mechanism. Based on favorable preclinical data in metastatic rhabdomyosarcoma and metastatic resistant neuroblastoma. In this IND proposes a Phase 1/2 trial to evaluate safety, tolerability, and early clinical signals in MYCN driven cancers including rhabdomyosarcoma, neuroblastoma, Wilms tumor, retinoblastoma and medulloblastoma and in MYCN driven neuroendocrine prostate cancer, TNBC, Ovarian Cancer, Small Cell Lung Cancer (SCLC) etc. 56
ELIGIBILITY CRITERIA
List inclusion criteria List exclusion criteria Age Category Minimum age Maximum age Gender
Inclusion Criteria For Childhood and Adolescent Cancers 1 6months-12 years, male and female., 13-18yrs male & female. 2 Diagnosis of Rhabdomyosarcoma, Neuroblastoma, Retinoblastoma, Wilms tumor, Medulloblastoma, and Acute lymphoblastic leukaemia 3 Fresh Tumor tissues or slides or blocks must be available for retrospective analysis. 4 Tumor biomarkers: MYCN+ tumor confirmed by IHC and or qPCR MYOD1+/- tumor confirmed by IHC and or qPCR TP53 +/- tumor confirmed by IHC and or qPCR 8 Measurable disease by RECIST version 1.1 9 Must have received previous treatment with the following medications: Olaparib, actinomycin D, cisplatin, cyclophosphamide, bevacizumab, epirubicin and paclitaxel. 10 Adequate bone marrow function: HB (g/dl) HCT (%) MCV (fl) RDW (%) PLT (10^3ml) WBC (10^3/ml) 6 months-2 years 11-13.5 31-42 73-85 12.3-15.6 150-350 6-17 2-6 years 11-13.7 34-44 75-86 12-14.6 150-350 5-15.5 6-12 years 11.2-14.5 35-44 78-90 11.9-13.8 150-350 4.5-13.5 12- <18 years female 11.4-14.7 36-46 80-96 11.9-14.6 150-350 4.5-13.5 12- <18 years male 12.4-16.4 40-51 80-96 11.9-13.7 150-350 4.5-13.5 > 18 years female 12-14 36-41 80-90 150-350 4.5-11 > 18 years male 13.5-15.5 41-47 80-90 150-350 4.5-11 11 Adequate cardiac function: left ventricular ejection fraction (LVEF) ≳ 55%, fractional shortening fraction (FS) ≳ 28% 12 Adequate neurologic function: In patients ≳ 16 years, ECOG/WHO performance status < 2 or Karnofsky performance ≳ 50. < 16 years, Lansky performance score > 50%. 13 No history of autoimmune disorder. 14 No history of coagulation or platelet disorders. 15 Able to receive medication intravenously. 16 Not pregnant or trying to conceive. 17 Not breastfeeding. Ability to give to informed consent or assent to consent. Rhabdomyosarcoma: Histological diagnosis of rhabdomyosarcoma (embryonal or alveolar) Past history or not of Surgery Past history or not of radiation therapy Past history of chemotherapy: Vincristine, Actinomycin D, Cyclophosphamide treatment Inclusion Criteria for Adults: 1. Adult patients (>18 years) 2. Biopsy-confirmed diagnosis of , neuroendocrine prostate cancer, Small Cell Lung Cancer, Glioblastoma multiforme, Spinal Ependymoma, T-cell acute lymphoblastic leukaemia, high grade serous ovarian cancer, basal cell carcinoma, Sarcomas, triple negative breast cancer (TNBC). 3. MYCN positivity (+, ++, +++) tested by histology at trial enrolment, or history of prior histologic diagnosis. 4. treatment for their cancer type with incurable advanced disease. 5. Performance status of 0 or 1 on Eastern Cooperative Oncology Group (ECOG) 6. Able to provide written informed consent at the time of study enrolment. 7. Participants who are physically able to become pregnant must use an effective form of birth control from 14 days prior to enrollment through 6 months following the last dose of 3’UTRMYCN M1-14. Participants who can father a child must use an effective form of birth control from Day 0 through 3 months following the last dose of 3’UTRMYCN M1-14. 8. Laboratory values (Hematology): Absolute neutrophil count ≥ 1,000 cells/mm3; Platelet count ≥ 75,000 cells/mm3; Hemoglobin ≥ 8.0 g/dL. 9. Laboratory values (Renal): Serum creatinine < 1.5 × upper limit of normal (ULN) or creatinine clearance ≥ 40 mL/min based on the Cockcroft-Gault glomerular filtration rate estimation 10. Laboratory values (Coagulation): Prothrombin/International Normalized Ratio (PT/INR) or prothrombin time must be < 1.5 × ULN; activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN unless undergoing anticoagulation therapy. 11. Laboratory values (Liver): Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2 × ULN; Bilirubin ≤ 2 × ULN or ≤ 5 × ULN for all patients. 12. Cardiovascular values (Heart): Patients will be ineligible if they have medical history of an arterial thrombotic event, stroke, or transient ischemic attack within the past 12 months; medical history of symptomatic congestive heart failure (New York Heart Association classes II-IV) or a cardiac arrhythmia that required treatment within the past 12 months; medical history of myocardial infarction or unstable angina within 6 months before Cycle 1 Day 1; QTcF prolongation to > 470 ms in women and > 450 ms in men based on a 12-lead electrocardiogram (ECG) in triplicate using the Fridericia formula: QTc = QT / RR1/3. 13. Pulmonary values (Lungs): No evidence of acute respiratory failure (PaO2 <65 mmHg on room air, or PaCO2 ≥ 50 or pH<7.35), chronic bronchitis (FEV1 ≤ 60% predicted or FVC ≤ 60%), acute bronchitis (increase in cough, sputum production, and sputum color within prior 5 days). Neuroendocrine Prostate Cancer (NEPC) inclusion criteria: 14. Neuroendocrine Prostate Cancer (NEPC) 15. Histologically or cytologically documented findings consistent with NEPC not amenable to curative surgery, radiation, or other therapy. 16. Prior treatment (for advanced, metastatic or [neo]adjuvant) should have included a taxane and/or anthracycline-based therapy, androgen receptor inhibitor, androgen deprivation therapy and, where appropriate, an approved checkpoint inhibitor. 17. MYCN positivity by histology (+, ++, +++) Small Cell Lung Cancer (SCLC) inclusion criteria: 23. Histologically or cytologically documented findings consistent with small cell lung cancer not amenable to curative surgery, radiation, or other therapy. 24. Failed the standard-of-care treatment for SCLC : Cisplatin or Carboplatin, etoposide , atezolizumab, durvalumab, Tarlatamab MYCN positivity by histology (+, ++, +++) Glioblastoma Multiforme (GBM) inclusion criteria: 28. Histologically or cytologically documented findings consistent with glioblastoma multiforme not amenable to curative surgery, radiation, or other therapy. 29. Failed radiation and chemotherapy including temozolomide and bevacizumab. 30. MYCN positivity by histology (+, ++, +++) High grade serous ovarian cancer inclusion criteria: 31. Histologically or cytologically documented findings consistent with ovarian cancer not amenable to curative surgery, radiation, or other therapy. 32. Failed platinum-based chemotherapy, such as cisplatin or carboplatin and in combination with a taxane (paclitaxel/docetaxel) 33. MYCN positivity by histology (+, ++, +++) T-Cell Acute Lymphoblastic Leukaemia inclusion criteria: Histological diagnosis of ALL Past history or not of radiation therapy Past history of chemotherapy (methotrexate, vincristine, dexamethasone) Past history of antibody drug conjugate treatment MYCN (+, ++, +++) Basal Cell Carcinoma Histological diagnosis of Basal Cell Carcinoma Past history or not of radiation therapy, phototherapy) Past history of chemotherapy (5-Fluorouracil, imiquimod) Past history of antibody drug conjugate treatment MYCN (+, ++, +++) Spinal Ependymoma Histological diagnosis of Spinal ependymoma Past history or not of radiation therapy Past history of chemotherapy (temozolomide, lapatinib) Past history of antibody drug conjugate treatment MYCN (+, ++, +++) Sarcomas Histological diagnosis of Sarcomas Past history or not of radiation therapy Past history of chemotherapy (Doxorubicin, ifosfamide, epirubicin, gemicitabine,docetaxel, dacarbazine Pazopanib, imatinib, sorafenib) Past history of antibody drug conjugate treatment MYCN (+, ++, +++) Triple Negative Breast Cancer (TNBC) 1. Triple negative breast cancer status confirmed on histology (HER2-, PR-, ER-) 2. Histologically or cytologically documented findings consistent with TNBC not amenable to curative surgery, radiation, or other therapy. 3. Prior treatment (for advanced, metastatic or [neo]adjuvant) should have included a taxane and/or anthracycline-based therapy and, where appropriate, an approved checkpoint inhibitor. 4. MYCN positivity by histology (+, ++, +++) 5. Presence or absence of PD-L1 by histology Exclusion criteria 1 Abnormal cardiac function: left ventricular ejection fraction (LVEF) < 55%, fractional shortening fraction (FS) < 28%. 2 Uncontrolled cardiac arrhythmia. 3 QTc prolongation on ECG. 4 Abnormal neurologic function: In patients ≳ 16 years, ECOG/WHO performance status > 2 or Karnofsky performance < 50. In patients < 16 years, Lansky performance score < 50%. 5 History of cerebrovascular accident. 6 Evidence of brain metastasis. 7 History of coagulopathy or platelet disorders. 7 History of autoimmune disorder. 9 Pregnant or breastfeeding. 10 Trying to conceive/refusing contraceptive use during the study period (in sexually active patients). Exclusion Criteria for Adults: 1. Previous mRNA drug treatment or currently being treated with other investigational agents. 2. Liver dysfunction or failure, renal failure, or severe cardio-respiratory disease. 3. Baseline reticulocytosis or monocytosis (>2xULN). 4. Significant medical illnesses that in the investigator’s opinion cannot be adequately controlled or would compromise the patient’s ability to tolerate therapy (e.g., history of allergic reactions attributed to compounds of similar chemical or biologic composition to 3’UTRMYCN M1-14). 5. Any history of other malignancies, unless in complete remission and off all therapy for that disease for a minimum of 3 years. 6. History of thromboembolic disorder or deep vein thrombosis, unless resolved and off therapeutic anticoagulation. 7. Presence of abnormal hematological or biochemical parameters as defined in this protocol (e.g., anemia, thrombocytopenia). 8. Active infection currently being treated with systemic antibiotics. 9. Pregnancy or lactation. 80 and over: 80+ Year,Adolescent: 13 Year(s)-17 Year(s),Adult: 18 Year(s)-44 Year(s),Aged: 65 Year(s)-79 Year(s),Child: 6 Year-12 Year,Infant: 1 Month(s)-12 Month(s),Infant: 13 Month(s)-24 Month(s),Middle Aged: 45 Year(s)-64 Year(s),New born: 0 Day-1 Month,Preschool Child: 2 Year-5 Year 6 Month(s) 100 Year(s) Both
ETHICS APPROVAL
Has the study received appropriate ethics committee approval Date the study will be submitted for approval Date of approval Name of the ethics committee
Yes 10/06/2026 National Health Research Ethics Committee of Nigeria NHREC
Ethics Committee Address
Street address City Postal code Country
Department of Health Planning and Research11th Floor, Federal Secretariat Complex, Phase IIIShehu Shagari Way, GarkiP.M.B. 083, Abuja, Nigeria Abuja 900001 Nigeria
OUTCOMES
Type of outcome Outcome Timepoint(s) at which outcome measured
Primary Outcome 8.6.1 Primary Outcome Measures 8.6.1.1 Safety and Tolerability 1. Measure: I. Incidence, severity, and nature of treatment-emergent adverse events (TEAEs) and dose-limiting toxicities (DLTs). 2. Assessment Method: I. Adverse events (AEs) and serious adverse events (SAEs) will be classified according to the Common Terminology Criteria for Adverse Events (CTCAE v5.0). II. DLTs will be assessed during Cycle 1 (first 28 days) of treatment to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D). III. Continuous monitoring of vital signs, laboratory parameters (hematology, liver/kidney function tests), electrocardiograms (ECG), and echocardiography. 3. Justification: I. Safety is the primary goal of a Phase 1 trial. II. The 3+3 dose-escalation design requires real-time assessment of DLTs to guide dose modifications and escalation. 8.6.1.2 Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) 1. Measure: I. Identification of the highest dose level at which ≤1 of 6 patients experiences a DLT. 2. Assessment Method: I. MTD will be determined through dose-escalation using the 3+3 design. II. RP2D will be selected based on MTD data, pharmacokinetics (PK), and additional safety/tolerability data from the dose-expansion phase. 3. Justification: I. Establishing the optimal dose is critical for advancing 3’UTRMYCN M1-14 to later-stage trials. 8.6.2 Secondary Outcome Measures 8.6.2.1 Preliminary Anti-Tumor Efficacy 1. Measure: I. Overall response rate (ORR) = (Complete Response [CR] + Partial Response [PR]) / Total efficacy-evaluable patients. II. Disease Control Rate (DCR) = (CR + PR + Stable Disease [SD]) / Total efficacy-evaluable patients. III. Progression-Free Survival (PFS): Time from treatment initiation to disease progression or death. IV. Overall Survival (OS): Time from treatment initiation to death from any cause. V. Duration of Response (DoR): Time from first response (CR/PR) to disease progression. 2. Assessment Method: I. Tumor response will be evaluated using Response Evaluation Criteria in Solid Tumors (RECIST v1.1). II. Imaging studies (MRI/CT scans) will be conducted at baseline, every 8 weeks, and upon disease progression. 3. Justification: I. Although a Phase 1 trial focuses primarily on safety, evaluating early efficacy signals helps determine whether further clinical development is warranted. 8.6.2.2 Pharmacokinetics (PK) Profile 1. Measure: I. Peak plasma concentration (Cmax). II. Time to peak concentration (Tmax). III. Area under the concentration-time curve (AUC). IV. Clearance (CL) and half-life (T½). 2. Assessment Method: I. Serial blood sampling at predefined time points post-dose. II. Drug concentration measured using liquid chromatography-mass spectrometry (LC-MS/MS). 3. Justification: I. PK analysis ensures the selected RP2D achieves therapeutic exposure while minimizing toxicity. 8.6.2.3 Pharmacodynamic (PD) Profile 1. Measure: I. MYCN mRNA degradation levels. II. MYCN protein downregulation. 2. Assessment Method: I. Tumor biopsy analysis (pre-treatment and on-treatment) using: a. Quantitative PCR (qPCR) for MYCN mRNA expression. b. Western blotting and immunohistochemistry (IHC) for MYCN protein reduction. 3. Justification: I. Confirming target engagement ensures that 3’UTRMYCN M1-14 is achieving its intended biological effect. 8.6.2.4 Immunogenicity and Off-Target Effects 1. Measure: I. Anti-drug antibody (ADA) formation. II. Cytokine profiling (IL-6, TNF-α, IFN-γ, etc.). III. Off-target gene expression changes. 2. Assessment Method: I. ELISA and flow cytometry for ADA detection. II. RNA sequencing to evaluate gene expression changes. 3. Justification: I. mRNA-based therapies may trigger immune responses, requiring close monitoring for unintended immunogenicity and specificity risks. 8.6.2.5 Patient-Reported Outcomes (PROs) and Quality of Life (QoL) 1. Measure: I. Pediatric QoL tools: a. PedsQL™ (Pediatric Qu As described by the schedule of assessment
Secondary Outcome 8.6.2 Secondary Outcome Measures 8.6.2.1 Preliminary Anti-Tumor Efficacy 1. Measure: I. Overall response rate (ORR) = (Complete Response [CR] + Partial Response [PR]) / Total efficacy-evaluable patients. II. Disease Control Rate (DCR) = (CR + PR + Stable Disease [SD]) / Total efficacy-evaluable patients. III. Progression-Free Survival (PFS): Time from treatment initiation to disease progression or death. IV. Overall Survival (OS): Time from treatment initiation to death from any cause. V. Duration of Response (DoR): Time from first response (CR/PR) to disease progression. 2. Assessment Method: I. Tumor response will be evaluated using Response Evaluation Criteria in Solid Tumors (RECIST v1.1). II. Imaging studies (MRI/CT scans) will be conducted at baseline, every 8 weeks, and upon disease progression. 3. Justification: I. Although a Phase 1 trial focuses primarily on safety, evaluating early efficacy signals helps determine whether further clinical development is warranted. 8.6.2.2 Pharmacokinetics (PK) Profile 1. Measure: I. Peak plasma concentration (Cmax). II. Time to peak concentration (Tmax). III. Area under the concentration-time curve (AUC). IV. Clearance (CL) and half-life (T½). 2. Assessment Method: I. Serial blood sampling at predefined time points post-dose. II. Drug concentration measured using liquid chromatography-mass spectrometry (LC-MS/MS). 3. Justification: I. PK analysis ensures the selected RP2D achieves therapeutic exposure while minimizing toxicity. 8.6.2.3 Pharmacodynamic (PD) Profile 1. Measure: I. MYCN mRNA degradation levels. II. MYCN protein downregulation. 2. Assessment Method: I. Tumor biopsy analysis (pre-treatment and on-treatment) using: a. Quantitative PCR (qPCR) for MYCN mRNA expression. b. Western blotting and immunohistochemistry (IHC) for MYCN protein reduction. 3. Justification: I. Confirming target engagement ensures that 3’UTRMYCN M1-14 is achieving its intended biological effect. 8.6.2.4 Immunogenicity and Off-Target Effects 1. Measure: I. Anti-drug antibody (ADA) formation. II. Cytokine profiling (IL-6, TNF-α, IFN-γ, etc.). III. Off-target gene expression changes. 2. Assessment Method: I. ELISA and flow cytometry for ADA detection. II. RNA sequencing to evaluate gene expression changes. 3. Justification: I. mRNA-based therapies may trigger immune responses, requiring close monitoring for unintended immunogenicity and specificity risks. 8.6.2.5 Patient-Reported Outcomes (PROs) and Quality of Life (QoL) 1. Measure: I. Pediatric QoL tools: a. PedsQL™ (Pediatric Quality of Life Inventory). b. PROMIS™ (Patient-Reported Outcomes Measurement Information System). II. Caregiver-reported burden assessments. 2. Assessment Method: I. Structured questionnaires and interviews at baseline, during treatment, and post-treatment follow-up. 3. Justification: I. Provides insights into symptom burden, functional well-being, and overall treatment experience. Post intervention
RECRUITMENT CENTRES
Name of recruitment centre Street address City Postal code Country
University of Nigeria Teaching Hospital Ituku Ozalla Enugu 400001, Nigeria
Nnamdi Azikiwe University Teaching Hospital Nnewi Nnewi 435101 Nigeria
Alex Ekwueme Federal University Teaching Hospital Ntezi Abba, Abakaliki Abakiliki 480108 Nigeria
University of Portharcourt Teaching Hospital Choba Rivers Rivers State 500272 Nigeria
FUNDING SOURCES
Name of source Street address City Postal code Country
UTR Therapeutics Inc 169 Madison Ave 2235, New York, NY 10016, US New York 10021 United States of America
SPONSORS
Sponsor level Name Street address City Postal code Country Nature of sponsor
Primary Sponsor UTR Therapeutics Inc 169 Madison Ave 2235, New York, NY 10016, US New York City 10021 United States of America Commercial Sector/Industry
COLLABORATORS
Name Street address City Postal code Country
CONTACT PEOPLE
Role Name Email Phone Street address
Scientific Enquiries Chidiebere Awah chidi@utrtherapeutics.com +13478426873 169 Madison Ave 2235, New York, NY 10016, US
City Postal code Country Position/Affiliation
New York 10021 United States of America CEO
Role Name Email Phone Street address
Public Enquiries David Asuzu david@utrtherapeutics.com +12038049771 169 Madison Ave 2235, New York, NY 10016, US
City Postal code Country Position/Affiliation
New York City United States of America Chief Medical Officer
Role Name Email Phone Street address
Principal Investigator Obumneme Ezeanosike ezeanosike.obum@gmail.com +2348036741420 CROSDAT Multidisciplinary Research Centre Alex Ekwueme Federal University Teaching Hospital Ebonyi State Nigeria
City Postal code Country Position/Affiliation
Abakiliki Nigeria Principal Investigator
REPORTING
Share IPD Description Additional Document Types Sharing Time Frame Key Access Criteria
Yes Result Dissemination. We will inform the participants the outcome of the trial. The result of the trial will be filed with several regulatory agencies worldwide and the result is published in reputable peer reviewed journals. Informed Consent Form,Study Protocol 6months after end of study The Sponsor or its designee will oversee data management activities, including quality checks and data cleaning, to guarantee data integrity. Any data queries arising during review will be resolved with the investigator or study site personnel as needed. Data protection and confidentiality will be ensured in compliance with applicable data privacy regulations. All patient data will be de-identified before inclusion in the study database, and secure systems will be used for data storage and transfer (i.e., encrypted, cloud-based servers). The sponsor will retain responsibility for actions delegated to third parties such as CROs or data management vendors. Records and documents relevant to this study will be retained by participating sites and the Sponsor for the period required by local regulations and Sponsor policies. Transfer, destruction, or archiving of records will follow applicable regulatory requirements and Sponsor instructions.
URL Results Available Results Summary Result Posting Date First Journal Publication Date
No
Result Upload 1: Result Upload 2: Result Upload 3: Result Upload 4: Result Upload 5:
Result URL Hyperlinks Link To Protocol
Result URL Hyperlinks
Changes to trial information
Section Name Field Name Date Reason Old Value Updated Value
Trial Information Trial description 13/07/2026 Updated background This First-in-Human (FIH) Phase 1 clinical trial of 3’UTRMYCN M1-14, an mRNA-based therapy targeting MYCN oncogene-driven pediatric and adult cancers, is designed to evaluate its safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), preliminary efficacy, and immunogenicity in pediatric and adult patients. The study’s primary and secondary objectives are outlined below: Primary Objective To evaluate the safety, tolerability, and dose-limiting toxicity (DLT) of 3’UTRMYCN M1-14 in pediatric patients with MYCN-driven solid tumors to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D). • Safety parameters will be assessed through: I. Adverse event (AE) monitoring per Common Terminology Criteria for Adverse Events (CTCAE v5.0). II. Vital sign measurements and laboratory evaluations (hematology, liver/kidney function tests). III. 3+3 dose-escalation methodology to guide dosing decisions. • Dose-Limiting Toxicities (DLTs) will be assessed based on: I. Occurrence of Grade 3 or higher toxicities in the first cycle (28 days). II. The dose level at which ≥2 patients in a cohort experience a DLT will be considered intolerable. III. The highest tolerable dose with ≤1 DLT per cohort will be designated as the MTD, and the RP2D will be determined accordingly. Secondary Objectives 1. To assess the preliminary anti-tumor efficacy of 3’UTRMYCN M1-14 as monotherapy and in combination with standard-of-care (SOC) therapies in MYCN-driven pediatric and adult cancers. • Efficacy endpoints include: I. Tumor response rate (complete response, partial response, stable disease, progressive disease) per Response Evaluation Criteria in Solid Tumors (RECIST v1.1). II. Progression-Free Survival (PFS) and Overall Survival (OS). • Exploration of combination therapy with standard chemotherapeutic agents (cisplatin, actinomycin D, cyclophosphamide, paclitaxel, epirubicin) to assess potential synergy and improved tumor control. 2. To characterize the pharmac Background Summary MYCN is over expressed in many cancers and has remained undruggable. We have pre-clinical evidence of the novel therapeutic agent, the 3'UTRMYCNM1-14+IO-Nanocage being effective in downregulating MYCN in pan MYCN driven cancers in-vivo such as in rhabdomyosarcoma, neuroblastoma, NEPC, SCLC and medulloblastoma. Therefore, the objective of this trial is to establish: 1. The safety and tolerability of the drug. 2. To determine the preliminary efficacy 3. To determine the PK/PD
Section Name Field Name Date Reason Old Value Updated Value
Trial Information Trial description 13/07/2026 PACTR Admin Background Summary MYCN is over expressed in many cancers and has remained undruggable. We have pre-clinical evidence of the novel therapeutic agent, the 3'UTRMYCNM1-14+IO-Nanocage being effective in downregulating MYCN in pan MYCN driven cancers in-vivo such as in rhabdomyosarcoma, neuroblastoma, NEPC, SCLC and medulloblastoma. Therefore, the objective of this trial is to establish: 1. The safety and tolerability of the drug. 2. To determine the preliminary efficacy 3. To determine the PK/PD Background Summary MYCN is over expressed in many cancers and has remained undruggable. We have pre-clinical evidence of the novel therapeutic agent, the 3'UTRMYCNM1-14+IO-Nanocage being effective in downregulating MYCN in pan MYCN driven cancers in-vivo such as in rhabdomyosarcoma, neuroblastoma, NEPC, SCLC and medulloblastoma. Therefore, the objective of this trial is to establish: 1. The safety and tolerability of the drug. 2. To determine the preliminary efficacy 3. To determine the PK/PD
Section Name Field Name Date Reason Old Value Updated Value
Outcome OutCome List 06/07/2026 Clarification on time points on which outcomes will be measured As described by the schedule of assessment, 66 Secondary Outcome, Post intervention, 8.6.2 Secondary Outcome Measures 8.6.2.1 Preliminary Anti-Tumor Efficacy 1. Measure: I. Overall response rate (ORR) = (Complete Response [CR] + Partial Response [PR]) / Total efficacy-evaluable patients. II. Disease Control Rate (DCR) = (CR + PR + Stable Disease [SD]) / Total efficacy-evaluable patients. III. Progression-Free Survival (PFS): Time from treatment initiation to disease progression or death. IV. Overall Survival (OS): Time from treatment initiation to death from any cause. V. Duration of Response (DoR): Time from first response (CR/PR) to disease progression. 2. Assessment Method: I. Tumor response will be evaluated using Response Evaluation Criteria in Solid Tumors (RECIST v1.1). II. Imaging studies (MRI/CT scans) will be conducted at baseline, every 8 weeks, and upon disease progression. 3. Justification: I. Although a Phase 1 trial focuses primarily on safety, evaluating early efficacy signals helps determine whether further clinical development is warranted. 8.6.2.2 Pharmacokinetics (PK) Profile 1. Measure: I. Peak plasma concentration (Cmax). II. Time to peak concentration (Tmax). III. Area under the concentration-time curve (AUC). IV. Clearance (CL) and half-life (T½). 2. Assessment Method: I. Serial blood sampling at predefined time points post-dose. II. Drug concentration measured using liquid chromatography-mass spectrometry (LC-MS/MS). 3. Justification: I. PK analysis ensures the selected RP2D achieves therapeutic exposure while minimizing toxicity. 8.6.2.3 Pharmacodynamic (PD) Profile 1. Measure: I. MYCN mRNA degradation levels. II. MYCN protein downregulation. 2. Assessment Method: I. Tumor biopsy analysis (pre-treatment and on-treatment) using: a. Quantitative PCR (qPCR) for MYCN mRNA expression. b. Western blotting and immunohistochemistry (IHC) for MYCN protein reduction. 3. Justification: I. Confirming target engagement ensures that 3’UTRMYCN M1-14 is achieving its intended biological effect. 8.6.2.4 Immunogenicity and Off-Target Effects 1. Measure: I. Anti-drug antibody (ADA) formation. II. Cytokine profiling (IL-6, TNF-α, IFN-γ, etc.). III. Off-target gene expression changes. 2. Assessment Method: I. ELISA and flow cytometry for ADA detection. II. RNA sequencing to evaluate gene expression changes. 3. Justification: I. mRNA-based therapies may trigger immune responses, requiring close monitoring for unintended immunogenicity and specificity risks. 8.6.2.5 Patient-Reported Outcomes (PROs) and Quality of Life (QoL) 1. Measure: I. Pediatric QoL tools: a. PedsQL™ (Pediatric Quality of Life Inventory). b. PROMIS™ (Patient-Reported Outcomes Measurement Information System). II. Caregiver-reported burden assessments. 2. Assessment Method: I. Structured questionnaires and interviews at baseline, during treatment, and post-treatment follow-up. 3. Justification: I. Provides insights into symptom burden, functional well-being, and overall treatment experience.